SB-462795: GSK began a Phase I trial

Human Genome Sciences Inc. (HGSI), Rockville, Md. GlaxoSmithKline plc (GSK; LSE:GSK), London, U.K. Product: SB-462795 Business: Muscoloskeletal Therapeutic category: Matrix remodeling Target: Catheps...